Predictive wild-type RAS/BRAF and pharmacogenetic biomarkers drive selection of metastatic colorectal cancer patients fit for intensive first-line FIr-C/FOx-C schedule adding cetuximab to triplet chemotherapy

被引：0
|
作者：
Russell, Mike
Lowenstein, Cassandra L.
Zhang, Xuqing
Roach, Jeremy
Song, Jianing
Nagilla, Rakesh
Orth, Peter
Tudor, Matt
Deng, Qiaolin
Sui, Zhihua
Strickland, Corey
Jolivette, Larry J.
Priestley, E. Scott
Mohammad, Helai P.
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-A052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A052
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Predictive wild type RAS/BRAF and pharmacogenetic biomarkers drive selection of metastatic colorectal cancer patients fit for intensive first-line Flr-C/F0x-C schedule adding cetuximab to triplet chemotherapy
    Bruera, Gemma
    Massacese, Silvia
    Dal Mas, Antonella
    Ficorella, Corrado
    Ciacco, Eugenio
    Calvisi, Giuseppe
    Simmaco, Maurizio
    Ricevuto, Enrico
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [2] Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers
    Bruera, Gemma
    Massacese, Silvia
    Pepe, Francesco
    Malapette, Umberto
    Mas, Antonella Dat
    Ciacco, Eugenio
    Calvisi, Giuseppe
    Troncone, Giancarlo
    Simmaco, Maurizio
    Ricevuto, Enrico
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [3] Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and individual limiting toxicity syndromes prediction by pharmacogenomic biomarkers
    Bruera, G.
    Massacese, S.
    Pepe, F.
    Malapelle, U.
    Dal Mas, A.
    Ciacco, E.
    Calvisi, G.
    Marchetti, P.
    Troncone, G.
    Simmaco, M.
    Ricevuto, E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.
    Bruera, Gemma
    Massacese, Silvia
    Pepe, Francesco
    Malapelle, Umberto
    Dal Mas, Antonella
    Ciacco, Eugenio
    Calvisi, Giuseppe
    Marchetti, Paolo
    Troncone, Giancarlo
    Simmaco, Maurizio
    Ricevuto, Enrico
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Intensive first-line triplet chemotherapy plus cetuximab FIr-C/FOx-C in RAS wild-type MCRC: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.
    Bruera, Gemma
    Massacese, Silvia
    Dal Mas, Antonella
    Ficorella, Corrado
    Ciacco, Eugenio
    Calvisi, Giuseppe
    Simmaco, Maurizio
    Ricevuto, Enrico
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [6] Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients
    Samalin, Emmanuelle
    Mazard, Thibault
    Assenat, Eric
    Rouyer, Magali
    de la Fouchardiere, Christelle
    Guimbaud, Rosine
    Smith, Denis
    Portales, Fabienne
    Ychou, Marc
    Adenis, Antoine
    Fiess, Catherine
    Lopez-Crapez, Evelyne
    Thezenas, Simon
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (08) : 1375 - 1381
  • [7] Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy
    Yamaguchi, Kensei
    Ando, Masahiko
    Ooki, Akira
    Beier, Frank
    Guenther, Silke
    von Hohnhorst, Philipp
    Van Cutsem, Eric
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : E29 - E37
  • [8] Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
    Geoffrey Y. Ku
    Benjamin A. Haaland
    Gilberto de Lima Lopes
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 231 - 238
  • [9] Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
    Ku, Geoffrey Y.
    Haaland, Benjamin A.
    Lopes, Gilberto de Lima, Jr.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 231 - 238
  • [10] First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Bobo Zheng
    Xin Wang
    Mingtian Wei
    Quan Wang
    Jiang Li
    Liang Bi
    Xiangbing Deng
    Ziqiang Wang
    BMC Cancer, 19
12345